Abstract
The antimicrobial properties of silver nanoparticles (AgNPs) have been widely acclaimed for decades. However, because of the physiological toxicity of silver-based nanosystems, the use of nano‑silver-based antimicrobial therapeutics, unlike synthetic therapeutics, is still progressing clinically. Nevertheless, the appearance of highly evolved drug-resistant microbial strains prompted the development of unconventional, multi-targeting therapeutics to replace conventional drugs. Also, the advent of surface engineering methods used to tailor the shape, size, and physicochemical properties of AgNPs followed by their functionalization and bioconjugation for maneuvering their interactions with physiological components resulted in improved physiological compatibility. Surface-engineered AgNPs also present workable solutions to deal with the intricacies of contemporary antimicrobial therapy, such as antimicrobial resistance. In addition, several formulations of surface-functionalized AgNPs exhibit synergistic oligodynamic inhibition of pathogenic microbes with commercial antimicrobial chemotherapeutics. This chapter presents the current status, perspectives, and potential for the development of surface-functionalized AgNPs as next-generation antimicrobials.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
